老年性乳腺癌临床特点及相关治疗研究进展
Research Progress on Clinical Features and Related Treatment of Senile Breast Cancer
DOI: 10.12677/ACM.2021.1112831, PDF,    科研立项经费支持
作者: 程 璇, 吴耀禄：延安大学附属医院腺体血管外科，陕西 延安
关键词: 老年性乳腺癌；病理特点；治疗；Senile Breast Cancer； Pathological Characteristics； Treatment
摘要: 随着世界老龄化程度的日益严重，老年乳腺癌患者所占比例逐渐增加，对其治疗也逐渐引起重视。但是与非老年性乳腺癌患者相较，老年性患者的合并症、脏器功能状况、年龄等众多因素等都可以对其生存情况及治疗选择产生影响。目前针对老年性乳腺癌患者的治疗没有明确的循证医学证据，大多是根据总人群的乳腺癌治疗指南结合临床医生的经验进行治疗。本文从老年性乳腺癌的临床病理特点、诊疗进展两大方面进行讨论，以期加深对老年性乳腺癌的认识及了解治疗方面的研究进展。
Abstract: With the increasing degree of aging in the world, the proportion of senile breast cancer patients gradually increases, and its treatment is gradually taken seriously. However, compared with non-senile breast cancer patients, the complications, organ function, age and many other factors of senile patients can have an impact on their survival status and treatment choice. At present, there is no clear evidence-based medical evidence for the treatment of senile patients with advanced breast cancer, mostly based on the breast cancer treatment guidelines of the total population combined with the experience of clinicians. This paper discusses the clinicopathological characteristics and progress of senile breast cancer in diagnosis and treatment, in order to deepen the understanding and the research progress of senile breast cancer.
文章引用：程璇, 吴耀禄. 老年性乳腺癌临床特点及相关治疗研究进展[J]. 临床医学进展, 2021, 11(12): 5613-5619. https://doi.org/10.12677/ACM.2021.1112831

参考文献

[1] 郑荣寿, 孙可欣, 张思维, 曾红梅, 邹小农, 陈茹, 顾秀瑛, 魏文强, 赫捷. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[2] 师金, 梁迪, 李道娟, 等. 全球女性乳腺癌流行情况研究[J]. 中国肿瘤, 2017, 26(9): 683-690.
[3] 陈万青, 郑荣寿. 中国女性乳腺癌发病死亡和生存状况[J]. 中国肿瘤临床, 2015, 42(13): 668-674.
[4] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2011) Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials. Lancet, 378, 771-784. [Google Scholar] [CrossRef] 
[5] Le Masters, T., Madhavan, S.S., Sambamoorthi, U., Hazard-Jenkins, H.W., Kelly, K.M. and Long, D. (2018) Receipt of Guideline-Concordant Care among Older Women with Stage I-III Breast Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network, 16, 703-710. [Google Scholar] [CrossRef] [PubMed]
[6] 宋延辉, 李晶, 吴涛, 冯晓冬, 罗丕福, 狄方. 70岁以上老年人乳腺浸润癌的临床病理分析[J]. 广东医学, 2019, 40(S1): 320-321+324.
[7] Pappo, I., Karni, T. and Sandbank, J. (2007) Breast Cancer in the Elderly: Histological, Hormonal and Surgical Characteristics. Breast, 16, 60-67. [Google Scholar] [CrossRef] [PubMed]
[8] Syed, B.M., Green, A.R. and Paish, E.C. (2013) Biology of Primary Breast Cancer in Older Women Treated by Surgery: With Correlation with Long-Term Clinical Outcome and Comparison with Their Younger Counterparts. British Journal of Cancer, 108, 1042-1051. [Google Scholar] [CrossRef] [PubMed]
[9] Wedding, U. and Höffken, K. (2003) Care of Breast Cancer in the Elderly Woman—What Does Comprehensive Geriatric Assessment (CGA) Help? Supportive Care in Cancer, 11, 769-774. [Google Scholar] [CrossRef] [PubMed]
[10] Gennari, R. and Audisio, R.A. (2008) Breast Cancer in Elderly Women. Optimizing the Treatment. Breast Cancer Research and Treatment, 110, 199-209. [Google Scholar] [CrossRef] [PubMed]
[11] Holmes, C.E. and Muss, H.B. (2003) Diagnosis and Treatment of Breast Cancer in the Elderly. CA: A Cancer Journal for Clinicians, 53, 227-244. [Google Scholar] [CrossRef] [PubMed]
[12] 方谭玮, 俸瑞发, 陈威. 老年乳腺癌组织中表皮生长因子受体2、雌激素受体、孕酮受体、P53和Ki67的表达及其临床意义[J]. 中华老年医学杂志, 2017, 36(2): 173-176.
[13] Tang, S.W., Parker, H., Winterbottom, L., Hassell, K., Ellis, I.O., Morgan, D.A. and Cheung, K.L. (2011) Early Primary Breast Cancer in the Elderly—Pattern of Presentation and Treatment. Surgical Oncology, 20, 7-12. [Google Scholar] [CrossRef] [PubMed]
[14] Wallwiener, C.W., Hartkopf, A.D. and Grabe, E. (2016) Adjuvant Chemotherapy in Elderly Patients with Primary Breast Cancer: Are Women ≥65 Undertreated? Journal of Cancer Research and Clinical Oncology, 142, 1847-1853. [Google Scholar] [CrossRef] [PubMed]
[15] Parks, R.M., Lakshmanan, R. and Winterbottom, L. (2012) Comprehensive Geriatric Assessment for Older Women with Early Breast Cancer—A Systematic Review of Literature. World Journal of Surgical Oncology, 10, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[16] Kalsi, T., Babic-Illman, G. and Ross, P.J. (2015) The Impact of Comprehensive Geriatric Assessment Interventions on Tolerance to Chemotherapy in Older People. British Journal of Cancer, 112, 1435-1444. [Google Scholar] [CrossRef] [PubMed]
[17] Decoster, L., Van Puyvelde, K. and Mohile, S. (2015) Screening Tools for Multidimensional Health Problems Warranting a Geriatric Assessment in Older Cancer Patients: An Update on SIOG Recommendations. Annals of Oncology, 26, 288-300. [Google Scholar] [CrossRef] [PubMed]
[18] De Santis, C., Siegel, R. and Bandi, P. (2011) Breast Cancer Statistics, 2011. CA: A Cancer Journal for Clinicians, 61, 409-418. [Google Scholar] [CrossRef] [PubMed]
[19] Muss, H.B., Berry, D.A. and Cirrincione, C. (2007) Cancer and Leukemia Group B Experience. Toxicity of Older and Younger Patients Treated with Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. Journal of Clinical Oncology, 25, 3699-3704. [Google Scholar] [CrossRef] 
[20] Zanuso, V., Fregoni, V., Gervaso, L. (2020) Side Effects of Adjuvant Chemotherapy and Their Impact on Outcome in Elderly Breast Cancer Patients: A Cohort Study. Future Science OA, 6, Article ID: FSO617. [Google Scholar] [CrossRef] [PubMed]
[21] Muss, H.B., Berry, D.A., Cirrincione, C.T. and Theodoulou, M. (2009) Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. New England Journal of Medicine, 360, 2055-2065. [Google Scholar] [CrossRef] 
[22] Berry, D.A., Cirrincione, C. and Henderson, I.C. (2006) Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients with Node-Positive Breast Cancer. JAMA, 295, 1658-1667. [Google Scholar] [CrossRef] [PubMed]
[23] Jones, S., Holmes, F.A., O’Shaughnessy, J., et al., (2009) Docetaxel with Cyclophosphamide Is Associated with an Overall Survival Benefit Compared with Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology, 27, 1177-1183. [Google Scholar] [CrossRef] [PubMed]
[24] Karavasilis, V., Papadimitriou, C., Gogas, H., et al. (2016) Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. Clinical Breast Cancer, 16, 291-298.e3. [Google Scholar] [CrossRef] [PubMed]
[25] Fisher, B., Dignam, J. and Bryant, J. (1996) Five versus More than Five Years of Tamoxifen Therapy for Breast Cancer Patients with Negative Lymph Nodes and Estrogen Receptor-Positive Tumors. Journal of the National Cancer Institute, 88, 1529-1542. [Google Scholar] [CrossRef] [PubMed]
[26] Santen, R.J. and Harvey, H.A. (1999) Use of Aromatase Inhibitors in Breast Carcinoma. Endocrine-Related Cancer, 6, 75-92. [Google Scholar] [CrossRef] [PubMed]
[27] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2015) Aromatase Inhibitors versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomised Trials. Lancet, 386, 1341-1352. [Google Scholar] [CrossRef] 
[28] 徐兵河, 张频. 绝经后早期乳腺癌芳香化酶抑制剂治疗相关的骨安全管理中国专家共识[J]. 中华肿瘤杂志, 2015, 37(7): 554-558.
[29] Kunkler, I.H., Williams, L.J. and Jack, W.J. (2015) PRIME II Investigators. Breast-Conserving Surgery with or without Irradiation in Women Aged 65 Years or Older with Early Breast Cancer (PRIME II): A Randomised Controlled Trial. Lancet Oncology, 16, 266-273. [Google Scholar] [CrossRef] 
[30] Stueber, T.N. and Diessner, J. (2020) Effect of Adjuvant Radiotherapy in Elderly Patients with Breast Cancer. PLoS ONE, 15, e0229518. [Google Scholar] [CrossRef] [PubMed]
[31] Molinaro, M., Ameri, P., Marone, G., et al. (2015) Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. BioMed Research International, 2015, Article ID: 138148. [Google Scholar] [CrossRef] [PubMed]
[32] Slamon, D.J., Leyland-Jones, B., Shak, S., et al. (2001) Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 344, 783-792. [Google Scholar] [CrossRef] 
[33] Perez, E.A., Romond, E.H., Suman, V.J., et al. (2011) Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 29, 3366-3373. [Google Scholar] [CrossRef] 
[34] Romond, E.H., Jeong, J.H., Rastogi, P., et al. (2012) Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) with ACP Plus Trastuzumab as Adjuvant Therapy for Patients with Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 30, 3792-3799. [Google Scholar] [CrossRef] 
[35] 孙金波. 保乳联合前哨淋巴结活检治疗老年乳腺癌患者的疗效[J]. 中国医药指南, 2020, 18(22): 138-139.
[36] 马辉. 保乳术联合前哨淋巴结活检在老年乳腺癌患者治疗中的应用价值[J]. 中国老年学杂志, 2016, 36(19): 4805-4806.
[37] 陈军, 江强. 前哨淋巴结活检联合保乳手术治疗老年乳腺癌的临床疗效[J]. 中国老年学杂志, 2016, 36(24): 6151-6152.

为你推荐